Opioid Dependence Clinical Trial
— NTX-SBXOfficial title:
Optimal Prevention of Overdose Deaths and Opioid Relapse Following Discharge: A Multi-Center RCT of Naltrexone Versus Buprenorphine in Norway
Verified date | October 2018 |
Source | University of Oslo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Persons dependent on opioids like heroin, morphine, or codeine have a high risk of relapse, overdose and overdose death. This risk is elevated even further following discharge from treatment or correctional institutions where patients have been detoxified. At the moment, state-of-the-art treatment is based on maintaining the dependence on opioids by daily intake of opioid medications like methadone or buprenorphine. Recently, a medication containing the blocking agent naltrexone was approved in the US; this does not maintain dependence but instead blocks heroin and other opioids for 28 days after intramuscular administration. This study will conduct a 12-week randomized comparison of naltrexone intramuscular suspension (XL-NTX) with daily buprenorphine-naloxone in OMT. Medication will start preceding discharge from a treatment or correctional facility to participating catchment regions in Norway. The main hypotheses are that XL-NTX will do equally well as - or better than - OMT on the proportion of biological samples negative for opioids, retention, self-reported use of alcohol and illicit drugs. Following the 12-week randomized period, there will be a 36-week period where participants can receive the study medication of their choice. After the end of the study, data from national registry databases can be collected for a further 12 months on outcomes such as recidivism, mortality and morbidity.
Status | Completed |
Enrollment | 166 |
Est. completion date | April 30, 2018 |
Est. primary completion date | August 31, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Opioid dependence (DSM-IV TR) - Age 18 or above - Applied & Approved for Norway's national OMT program - Discharge within 30 days of inclusion from a controlled environment; e.g. inpatient treatment or correctional (prison) facility - Voluntarily seeking treatment for opioid dependence Exclusion Criteria: - Pregnant or breast-feeding - Acute or recurring severe psychiatric disorder, e.g. psychosis, suicidality - Serious debilitation of liver or renal function (e.g. Child-Pugh level C) - Use of excluded medication - Known intolerance to study drugs or their ingredients - Employment in firm manufacturing one of the study drugs or close relation to such person |
Country | Name | City | State |
---|---|---|---|
Norway | Haukeland University Hospital | Bergen | Hordaland |
Norway | Akershus University Hospital | Oslo | Akershus |
Norway | Oslo University Hospital, Avdeling for Rus og Avhengighet | Oslo | |
Norway | Stavanger University Hospital | Stavanger | Rogaland |
Norway | Vestfold Hospital Trust | Tonsberg | Vestfold |
Lead Sponsor | Collaborator |
---|---|
University of Oslo | Haukeland University Hospital, Helse Stavanger HF, Norwegian Institute of Public Health, Oslo University Hospital, Ostfold Hospital Trust, The Hospital of Vestfold, The Research Council of Norway, The Royal Norwegian Ministry of Health, University Hospital, Akershus |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of biological samples negative/positive for opioid agonists | Week 1-12 post discharge | ||
Primary | Retention | Week 1-12 post discharge | ||
Primary | Days of use or abstinence from opioids | Week 1-12 post discharge | ||
Secondary | Use of other substances of abuse | Week 1-48 | ||
Secondary | Mental health | Self-reported mental health | Week 1-12 or 1-48 | |
Secondary | Somatic health | Self-reported and/or assessed by study personnel | Week 1-12 or 1-48 post discharge | |
Secondary | Psychosocial problems | Psychosocial problems like recidivism, employment, family problems. Self-reported or registry-based. | Week 1-12, Week 1-48, & Wk 49-100 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03675386 -
Reducing Opioid Use for Chronic Pain Patients Following Surgery
|
N/A | |
Completed |
NCT02593474 -
Medication-Assisted Treatment for Youth With Substance Use Disorders
|
Phase 1 | |
Completed |
NCT02294253 -
Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone
|
Phase 2/Phase 3 | |
Completed |
NCT02282306 -
Phone Interview to Prevent Recurring Opioid Overdoses
|
N/A | |
Completed |
NCT01592461 -
Starting Treatment With Agonist Replacement Therapies Follow-up Study
|
N/A | |
Terminated |
NCT00768482 -
A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence
|
Phase 3 | |
Completed |
NCT01741350 -
Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users
|
N/A | |
Terminated |
NCT04121546 -
Collaborative Care for Opioid Dependence And Pain Pilot Study
|
N/A | |
Withdrawn |
NCT03368794 -
Naloxone to TReatment Entry in the Emergency Setting
|
N/A | |
Completed |
NCT03447743 -
Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder
|
Early Phase 1 | |
Completed |
NCT04464421 -
SMART Effectiveness Trial
|
N/A | |
Recruiting |
NCT04189523 -
Does Early Administration of Ultrasound Guided Regional Anesthesia for Long Bone Fractures Effect Long Term Patient Opioid Usage
|
N/A | |
Completed |
NCT03305666 -
Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures
|
Phase 4 | |
Recruiting |
NCT04003948 -
Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification
|
Phase 2 | |
Not yet recruiting |
NCT03813095 -
Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction
|
Phase 2 | |
Terminated |
NCT02935101 -
Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants
|
Phase 2 | |
Completed |
NCT01895270 -
Improving Buprenorphine Detoxification Outcomes With Isradipine
|
Phase 1/Phase 2 | |
Completed |
NCT01425060 -
Improving Effective Contraceptive Use Among Opioid-maintained Women
|
Phase 1 | |
Completed |
NCT02324725 -
Biomarkers of Injectable Extended Release Naltrexone Treatment
|
Phase 4 | |
Completed |
NCT01262092 -
Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals
|
Phase 2 |